Biopharma Layoff Tracker 2024: Two Companies Lay Off Most of Workforce Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs. https://hubs.li/Q02DWxVB0 #layoffs #pharma #biotech #biospace
BioSpace
Internet News
West Des Moines, Iowa 111,257 followers
The leading source for biopharma news and jobs. Connecting industry pioneers with talented professionals.
About us
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.
- Website
-
http://www.biospace.com/
External link for BioSpace
- Industry
- Internet News
- Company size
- 11-50 employees
- Headquarters
- West Des Moines, Iowa
- Type
- Privately Held
- Founded
- 1985
- Specialties
- biotech jobs, pharma jobs, biotech news, pharma news, and life sciences news
Locations
-
Primary
3001 Westown Pkwy
#101
West Des Moines, Iowa 50266, US
Employees at BioSpace
-
Greg Slabodkin
-
Dr. D. Martin Alexander Gershon, MD, JD, MPH
AI & Digital Health Innovation Keynote•Linkedin “Top Voice” Venture Capital, Entrepreneurship, & Fundraising•Techstars Sr EIR•Goldman…
-
Angela Gabriel
Content Manager (Life Sciences Careers) at BioSpace
-
Lori Ellis (Katz)
Head of Insights
Updates
-
Pyzchiva, developed by Samsung Bioepis will be commercialized in the U.S. by Sandoz with the license period beginning on Feb. 22, 2025, according to a settlement and licensing agreement with Johnson & Johnson. https://hubs.li/Q02DWM5l0 #pharma #biospace
Samsung Bioepis Gets FDA Approval for Biosimilar of J&J’s Stelara | BioSpace
biospace.com
-
Due to Bristol Myers Squibb's ongoing portfolio reprioritization, Eisai US is taking over the development and commercialization of farletuzumab ecteribulin, an investigational antibody-drug conjugate targeting solid tumors. https://hubs.li/Q02DWMm90 #pharma #biospace
Eisai Assumes Sole Responsibility for ADC After Collaboration With BMS Ends | BioSpace
biospace.com
-
The FDA’s calendar is relatively light in July, with only five major deadlines, including one for a PD-1 blocker and another for an opioid overdose drug. https://hubs.ly/Q02DSnLy0 #pharma #biospace
FDA Action Alert: Arcutis, Orexo, Phantom and More | BioSpace
biospace.com
-
Gilead Sciences' blockbuster antibody-drug conjugate Trodelvy has encountered some clinical speed bumps in 2024 in bladder and lung cancer. Still, analysts remain bullish on its prospects in the oncology space. https://hubs.ly/Q02DSB8H0 #pharma #biospace
Gilead’s Trodelvy Stumbles in Late-Stage Trials But Remains Prized Cancer Asset | BioSpace
biospace.com
-
Daiichi Sankyo US has secured a victory in its patent arbitration with Seagen nabbing a $47 million award for attorneys’ fees and other costs, plus interest. However, a larger patent battle with Pfizer remains. https://hubs.ly/Q02DSzLD0 #pharma #biospace
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms | BioSpace
biospace.com
-
Psychedelic drug developers are homing in on the potential $16 billion depression treatment market, with a particular focus on treatment-resistant depression. https://hubs.li/Q02DStKj0 #pharma #biospace
Depression Is Notoriously Difficult to Treat. Can Psychedelic Therapies Help? | BioSpace
biospace.com
-
In a potential challenge to Pfizer's Prevnar 20, Merck's Capvaxive has been recommended by the Centers for Disease Control and Protection for use in preventing invasive pneumococcal disease in adults. https://hubs.li/Q02DSvTg0 #pharma #biospace
CDC Backs Merck’s Capvaxive, Tees Up Pneumococcal Competition With Pfizer | BioSpace
biospace.com
-
Industry experts provide clinical trial design and protocol suggestions for psychedelic drug developers after an advisory committee voted against approving Lykos Therapeutics' MDMA-assisted PTSD therapy. https://hubs.li/Q02DSnrB0 #pharma #biospace
Psychiatric Drug Developers Make Recommendations Following Lykos Adcomm | BioSpace
biospace.com
-
The U.S. Supreme Court on Friday overturned the long-standing Chevron doctrine, which required courts to defer to federal agencies and their interpretation of statutes, putting potential limits on the FDA's regulatory decisions. https://hubs.li/Q02DSlZk0
Supreme Court’s Chevron Doctrine Ruling Could Limit FDA’s Regulatory Authority | BioSpace
biospace.com